Browsing by Author "Reygagne P."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    ItemMetadata only
    Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
    (2025-01-01) Meah N.; Li J.; Wall D.; York K.; Bhoyrul B.; Bokhari L.; Coulthard L.; Asfour L.; Abraham L.S.; Asz-Sigall D.; Bergfeld W.F.; Betz R.C.; Blume-Peytavi U.; Callender V.; Chitreddy V.; Combalia A.; Cotsarelis G.; Craiglow B.; Dhurat R.; Dlova N.; Donovan J.; Doroshkevich A.; Eisman S.; Farrant P.; Gadzhigoroeva A.; Green J.; Grimalt R.; Harries M.; Hordinsky M.; Irvine A.D.; Jolliffe V.; Kaiumov S.; King B.; Kossard S.; Lee J.; Lee W.S.; Lortkipanidze N.; McMichael A.; Atanaskova Mesinkovska N.; Messenger A.; Mirmirani P.; Olsen E.; Orlow S.J.; Ovcharenko Y.; Piraccini B.M.; Pirmez R.; Rakowska A.; Reygagne P.; Roberts J.; Rudnicka L.; Saceda-Corralo D.; Shapiro J.; Sharma P.; Silyuk T.; Suchonwanit P.; Takwale A.; Tosti A.; Visser W.I.; Vañó-Galván S.; Vogt A.; Wade M.; Yip L.; Zlotogorski A.; Zhou C.; Sinclair R.; Meah N.; Mahidol University
    Background: As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objective: To produce an international consensus statement on the treatment modalities and prognostic indicators of FFA. Methods: Sixty-nine hair experts from six continents were invited to participate in a three-round Delphi process. The final stage was held as a virtual meeting facilitated via Zoom. The consensus threshold was set at ≥66%. Results: Of 365 questions, expert consensus was achieved in 204 (56%) questions following completion of the three rounds. Three additional questions were included at the final meeting. The category with the strongest consensus agreement was disease monitoring (9; 100%). Questions pertaining to physical therapies achieved the least category consensus (15; 40%), followed by systemic therapy (45; 43%). Limitations: The study lacked sufficient representation from Africa and South America. Conclusion: SOFFIA highlights areas of agreement and disagreement among experts. Robust research is warranted to provide evidence-based treatment recommendations.
  • No Thumbnail Available
    ItemMetadata only
    The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results from a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity
    (2024-01-01) Moussa A.; Bennett M.; Wall D.; Meah N.; York K.; Bokhari L.; Asfour L.; Rees H.; Abraham L.S.; Asz-Sigall D.; Basmanav F.B.; Bergfeld W.; Betz R.C.; Bhoyrul B.; Blume-Peytavi U.; Callender V.; Chitreddy V.; Combalia A.; Cotsarelis G.; Craiglow B.; Dhurat R.; Donovan J.; Doroshkevich A.; Eisman S.; Farrant P.; Ferrando J.; Gadzhigoroeva A.; Green J.; Grimalt R.; Harries M.; Hordinsky M.; Irvine A.; Jolliffe V.; Kaiumov S.; King B.; Lee J.; Lee W.S.; Li J.; Lortkipanidze N.; McMichael A.; Mesinkovska N.A.; Messenger A.; Mirmirani P.; Olsen E.; Orlow S.J.; Ovcharenko Y.; Piraccini B.M.; Pirmez R.; Rakowska A.; Reygagne P.; Rudnicka L.; Corralo D.S.; Senna M.; Shapiro J.; Sharma P.; Siliuk T.; Starace M.; Suchonwanit P.; Takwale A.; Tosti A.; Vañó-Galván S.; Visser W.I.; Vogt A.; Wade M.; Yip L.; Zhou C.; Sinclair R.; Moussa A.; Mahidol University
    Importance: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. Objective: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). Evidence Review: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022. Findings: Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. Conclusions and Relevance: This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure various disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity..